Boston Scientific (NYSE:BSX) made waves this month when it recalled and retired its Lotus TAVR product line.
Subsequent layoffs, first in Minnesota, then in Ireland, highlighted the impact of the decision to pull Lotus from the highly competitive market as a result of complexities related to the product delivery system and solely that — as the valve has achieved positive and clinically effective performance post-implant.